SDOX

SDOX, a Doxorubicin (DOX) prodrug, selectively releases the active agent, DOX, in tumor cells with elevated glutathione (GSH) levels, thereby reducing inadvertent adverse effects on healthy tissues while maintaining therapeutic efficacy [1].